Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN CARLOS, CALIF., AUG. 05, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SAN CARLOS, CALIF., JULY 24, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF JULIANNE AVERILL TO ITS BOARD OF DIRECTORS (THE BOARD), EFFECTIVE JULY 22, 2025.

BIOMEA FUSION APPOINTS JULIANNE AVERILL TO ITS BOARD OF DIRECTORS

SAN CARLOS, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THE PRESENTATION OF NEW PRECLINICAL AND CLINICAL DATA FOR ICOVAMENIB, THE COMPANY'S INVESTIGATIONAL ORAL MENIN INHIBITOR, AT THE 85TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA) JUNE 2023, 2025 IN CHICAGO.

BIOMEA FUSION PRESENTS NEW PRECLINICAL AND CLINICAL DATA ON ICOVAMENIB AT THE 85TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA)

DOSE-DEPENDENT, MARKED REDUCTIONS IN FOOD INTAKE AND SIGNIFICANT WEIGHT LOSS OBSERVED IN OBESE CYNOMOLGUS MONKEYS BMF-650 COMPARED FAVORABLY TO PUBLISHED DATA OF A LEADING GLP-1 RA CANDIDATE IND FILING ON TRACK FOR THE SECOND HALF OF 2025; WITH PHASE I STUDY INITIATION IN OBESE, OTHERWISE HEALTHY VOLUNTEERS ANTICIPATED LATE 2025 REDWOOD CITY, CALIF., JUNE 18, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED NEW PRECLINICAL FINDINGS FROM A 28-DAY WEIGHT LOSS STUDY IN OBESE NON-HUMAN PRIMATES EVALUATING BMF-650, THE COMPANY'S INVESTIGATIONAL, NEXT-GENERATION ORAL SMALL MOLECULE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA).

BIOMEA FUSION REPORTS PRECLINICAL DATA FOR BMF-650, A NEXT-GENERATION ORAL GLP-1 RECEPTOR AGONIST CANDIDATE, DEMONSTRATING ROBUST WEIGHT LOSS AND APPETITE SUPPRESSION IN OBESE NON-HUMAN PRIMATES

REDWOOD CITY, CALIF., JUNE 17, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 19,450,000 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE AN AGGREGATE OF 19,450,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND (II) IN LIEU OF COMMON STOCK, TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 550,000 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE AN AGGREGATE OF 550,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), AT AN EXERCISE PRICE OF $0.0001 PER PRE-FUNDED WARRANT.

BIOMEA FUSION ANNOUNCES PRICING OF PUBLIC OFFERING OF SECURITIES

REDWOOD CITY, CALIF., JUNE 17, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF).

BIOMEA FUSION ANNOUNCES PROPOSED PUBLIC OFFERING OF SECURITIES

NEW CLINICAL RESULTS SHOW SUSTAINED CRI, DEEP BONE MARROW RESPONSES, AND ENCOURAGING SURVIVAL IN FLT3-MUTANT AML PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH GILTERITINIB NEW CLINICAL RESULTS SHOW SUSTAINED CRI, DEEP BONE MARROW RESPONSES, AND ENCOURAGING SURVIVAL IN FLT3-MUTANT AML PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH GILTERITINIB

BIOMEA FUSION PRESENTS UPDATED PRELIMINARY CLINICAL DATA FOR COVALENT FLT3 INHIBITOR BMF-500 IN RELAPSED OR REFRACTORY ACUTE LEUKEMIA AT EHA 2025

REDWOOD CITY, CALIF., MAY 14, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT PRELIMINARY CLINICAL DATA FROM THE PHASE I COVALENT-103 TRIAL OF BMF-500 IN ADULTS WITH ACUTE LEUKEMIA (AL) WERE SELECTED FOR A POSTER PRESENTATION AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2025 CONGRESS, TAKING PLACE JUNE 1215 IN MILAN, ITALY.

BIOMEA FUSION'S BMF-500 SELECTED FOR POSTER PRESENTATION AT EHA 2025 HIGHLIGHTING PHASE I DATA IN RELAPSED/REFRACTORY ACUTE LEUKEMIA

COMPANY ANNOUNCES STRATEGIC REALIGNMENT TO FOCUS ON CORE PROGRAMS AND EXTEND CASH RUNWAY ICOVAMENIB PROGRESSING TOWARD THE NEXT PHASE OF CLINICAL DEVELOPMENT IN INSULIN DEFICIENTTYPE 2 DIABETES PATIENTS AND PATIENTS THAT ARE CURRENTLY UNCONTROLLED ON A GLP-1 BASED THERAPY BIOMEA'S NEXT GENERATION ORAL GLP-1 RECEPTOR AGONIST (BMF-650) FILING FOR IND ALL OTHER CLINICAL AND PRECLINICAL ACTIVITIES ARE EITHER BEING PARTNERED OR CLOSED REDWOOD CITY, CALIF., MAY 05, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

REDWOOD CITY, CALIF., APRIL 01, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT ON MARCH 23, 2025, THE COMPENSATION COMMITTEE OF BIOMEA'S BOARD OF DIRECTORS GRANTED TWO NEW EMPLOYEES NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 30,000 SHARES OF THE COMPANY'S COMMON STOCK. THE SHARES UNDERLYING EACH EMPLOYEE'S STOCK OPTIONS WILL VEST 1/16 ON A QUARTERLY BASIS OVER FOUR YEARS, IN EACH CASE SUBJECT TO EACH SUCH EMPLOYEE'S CONTINUED EMPLOYMENT WITH THE COMPANY ON SUCH VESTING DATES. ALL OF THE ABOVE-DESCRIBED AWARDS WERE MADE UNDER BIOMEA'S 2023 INDUCEMENT EQUITY PLAN (THE PLAN).

Biomea Fusion, Inc.

BMEA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biomea Fusion, Inc.

BMEA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BMEA